Breast cancer incidence, mortality and mortality-to-incidence ratio (MIR) are associated with human development, 1990–2016: evidence from Global Burden of Disease Study 2016
- 194 Downloads
To examine breast cancer burden in females using incidence, mortality and mortality-to-incidence ratio (MIR) and its association with human development.
We employ the data of breast cancer in females from the Global Burden of Disease 2016 study for the period 1990 to 2016 for 102 countries. Human development is measured using the human development index (HDI). 5-year survival rate of breast cancer is proxied using the mortality-to-incidence ratio (MIR).
Globally, breast cancer has claimed 535341 female lives and 1.7 million incident cases had surfaced in 2016. High incidence rates were observed in very high HDI countries led by the Netherlands (117.2/100,000), whereas the mortality rate was high in low/medium HDI countries led by Afghanistan (35.4/100,000). Breast cancer incidence has more than doubled in 60/102 countries, whereas deaths have doubled in 43/102 countries. Globally, breast cancer MIR decreased from 0.41 to 0.32 over 1990–2016 and displayed negative gradient with HDI (r = − 0.87), indicating a low 5-year survival in less developed countries.
Heterogeneity in breast cancer burden, as per human development, and increasing breast cancer incidence and low survival rates, indicated by MIR, call for broader human development, improving breast cancer awareness, and cost-effective screening and treatment in less developed countries.
KeywordsBreast cancer Incidence Mortality Mortality-to-incidence ratio (MIR)
Compliance with ethical standards
Conflict of interest
The authors of the paper declare no conflict of interest.
- 1.GBD 2016 Cause of Death Collaborators. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2016;390(10100):1151–210.Google Scholar
- 2.Global Burden of Disease Cancer Collaborators. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990–2016. a systematic analysis for the Global Burden of Disease Study. JAMA Oncol. 2018. https://doi.org/10.1001/jamaoncol.2018.2706.Google Scholar
- 8.Wang CC, Tsai MC, Peng CM, Lee HL, Chen HY, Yang TW, et al. Favorable liver cancer mortality-to-incidence ratios of countries with high health expenditure. Eur J Gastroenterol Hepatol. 2017;29(12):1397–401.Google Scholar
- 12.Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2016. (GBD 2016). 2017. Results. Seattle, United States: Institute for Health Metrics and Evaluation (IHME). http://ghdx.healthdata.org/gbd-results-tool. Accessed 5 July 2018.
- 13.United Nations Development Program (UNDP). Human Development Database. 2018. http://hdr.undp.org/en/data#. Accessed 30 June 2018 and 1 July 2018.
- 19.WHO Guide for effective programmes; cancer control: knowledge into action; module 3: early detection (free full text). 2018. http://www.who.int/cancer/publications/cancer_control_detection/en/. Accessed 6 Aug 2018.
- 27.Luthar UK. Clinical downstaging of cancer of the uterine cervix e an interim strategy for developing countries. In: Proceedings of the UICC congress. 1994.Google Scholar
- 29.World Bank Database. 2018. WDI data. http://databank.worldbank.org/data. Accessed 25 July 2018.